KPL

Kwality Pharmaceuticals Ltd.

BSE: 539997

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

3,361.10-273.7 (-7.53%)

21 Aug, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

64.6 / 100

Value Score

34.3 / 100

Price Momentum Score

96.7 / 100

QVM Score

80.1 / 100

Key Metrics

Market Cap

3487.48

P/E (TTM)

51.78

P/B

10.52

P/S (TTM)

0.21

EV/EBITDA

30.57

CAPE (5Y)

64.50

ROE (TTM)

22.61

ROCE (TTM)

23.57

ROA (TTM)

12.96

Avg 3Y ROE

16.71

Earnings 3Y CAGR

51.48

Sales 3Y CAGR

306.10

Sales 5Y CAGR

13.94

Debt/Equity

0.39

Consensus TP

Strong Buy %

Promoter Holding

54.86

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Kwality Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 96.7 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

96.7 / 100

High and improving ROE

The company reported strong ROE of 22.61% for 12-month ended 30 Jun 2026 and ROE improved by 628 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 19.57% for 12-month ended 30 Jun 2026 and operating margin improved by 258 bps from 1 year ago

What is Operating profit margin?

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 4040.18% for 12-month ended 30 Jun 2026 and the growth was 4029.59 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 4040.18

-99.6111701.8

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 69.01% for 12-month ended 30 Jun 2026 and the growth was 61.81 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.39 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.04 in the last 1 year

What is Debt to Equity?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 51.78 indicates that the stock is expensive on a standalone basis and is at a 68.66% premium to industry median P/E

What is P/E Ratio?

Median: 30.7

Value 51.78

-0.84752.64

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 34.7 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

34.7 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Kwality Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Kwality Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Kwality Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Sep 2018	Mar 2019	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	50.14	50.14	50.14	51.52	51.52	54.13	54.24	54.24	54.43	54.45	54.45	54.45	54.74	54.74	54.77	54.77	54.83	54.83	54.83	54.83	54.83	54.83	54.83	54.83	54.87	54.86
Indian Promoter	50.14	50.14	50.14	51.52	51.52	54.13	54.24	54.24	54.43	54.45	54.45	54.45	54.74	54.74	54.77	54.77	54.83	54.83	54.83	54.83	54.83	54.83	54.83	54.83	54.87	54.86
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	-	-	-	-	-	-	-	-	-	-	0.00	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.02	0.03	0.32	0.33	0.33	0.83	3.15	3.69
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	2.79	3.13
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03	0.32	0.33	0.33	0.33	0.36	0.56
Non-Institution	49.86	49.86	49.86	48.48	48.48	45.87	45.76	45.76	45.57	45.55	45.55	45.54	45.25	45.25	45.22	45.22	45.17	45.17	45.15	45.14	44.86	44.84	44.84	44.34	41.98	41.44
Bodies Corporate	20.28	-	19.62	19.30	19.47	19.53	16.67	15.80	15.40	15.29	12.99	12.97	10.07	7.27	4.31	3.10	3.23	3.27	2.56	2.14	1.91	1.92	1.79	2.10	1.22	1.34
Others (incl. Retail) No. of shareholders	29.58 169	49.86 171	30.24 145	29.18 141	29.01 128	26.34 131	29.09 145	29.96 347	30.17 552	30.26 1,021	32.56 4,165	32.57 5,339	35.18 6,161	37.98 6,884	40.91 6,229	42.12 5,725	41.94 5,639	41.90 5,216	42.59 7,416	43.00 8,879	42.95 9,351	42.92 10,044	43.05 11,518	42.24 10,628	40.76 10,473	40.10 13,168

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

Kwality Pharmaceuticals Ltd. is not part of any tracked index.

Prominent Investor Holdings

Dheeraj Kumar Lohia and Associates

Jun 2026

1.66%

₹ 58 Cr

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Kwality Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Aastha Seth Directors Immediate Relative	March-2026	Market Purchase (Acquisition) 18th Mar 2026	0.00 %	₹ 1,592.12	1.00 k	₹ 15.92 lac
RAMESH KUMAR Promoter	March-2026	Market Purchase (Acquisition) 6th Mar 2026	26.01 %	₹ 1,556.85	1.95 k	₹ 30.33 lac
AJAY KUMAR ARORA Promoter	March-2026	Market Purchase (Acquisition) 5th Mar 2026	13.59 %	₹ 1,585.02	941.00	₹ 14.91 lac
AJAY KUMAR ARORA Promoter	March-2026	Market Purchase (Acquisition) 5th Mar 2026	13.59 %	₹ 1,585.02	941.00	₹ 14.91 lac
ADITYA ARORA Promoter Group	March-2026	Market Purchase (Acquisition) 5th Mar 2026	11.95 %	₹ 1,585.08	948.00	₹ 15.03 lac
ADITYA ARORA Promoter Group	March-2026	Market Purchase (Acquisition) 5th Mar 2026	11.95 %	₹ 1,585.08	948.00	₹ 15.03 lac
ADITYA ARORA Promoter Group	February-2024	Market Purchase (Acquisition) 17th Feb 2024	11.89 %	₹ 485.31	4.92 k	₹ 23.87 lac
ADITYA ARORA Promoter Group	July-2023	Market Purchase (Acquisition) 4th Jul 2023	11.86 %	₹ 302.55	3.20 k	₹ 9.68 lac
ADITYA ARORA Promoter Group	June-2022	Market Purchase (Acquisition) 29th Jun 2022	6.85 %	₹ 353.22	1.41 k	₹ 4.98 lac
ADITYA ARORA Promoter Group	February-2022	Market Purchase (Acquisition) 26th Feb 2022	6.55 %	₹ 445.00	5.60 k	₹ 24.92 lac

Corporate Actions

History of Kwality Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Bonus1 new shares for 1 existing shares
Ex-date: 11th Oct 2017Announced on: 5th Sep 2017
Dividend₹ 0.60/share
Record date: 6th Jan 2017Ex-date: 5th Jan 2017
Announced on: 22nd Dec 2016

Company Profile

Overview of Kwality Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Kwality Pharmaceuticals Limited is an India-based company, which engages in the manufacturing & trading in pharmaceuticals & allied products. It engages in the business of manufacturers, buyers and sellers of and dealers in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical...

Key personnel

Mr. Gurpreet Kaur

Compliance Officer, Company Secretary

Mr. Shankar Dayal

Chief Domestic Sales Officer

Mr. Neeraj Lakhanpal

Chief Export Sales Officer

Mr. Lakhvinder Singh

Chief Designing Officer

Mr. Karunakar K. Tiwari

Chief Pharmacist

Mr. Aditya AroraD

Chief Financial Officer, Executive Director

Mr. Ramesh KumarD

Managing Director, Whole Time Director

Mr. Ajay Kumar AroraD

Whole Time Director

View all

Incorporated on

04 May 1983

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

1,137

IPO date

18 Jul 2016

Free Float

23,35,344

Website

https://www.kwalitypharma.com/

Phone no.

+911832774321

Address

Vill.Nag Kalan,Majitha Road, AMRITSAR, 143601, India

Frequently Asked Questions

What is the current share price of Kwality Pharmaceuticals Ltd.?

The current share price of Kwality Pharmaceuticals Ltd. is ₹ 3,361.10 as of 21 Aug 2026.

What is the market capitalisation of Kwality Pharmaceuticals Ltd.?

The market capitalisation of Kwality Pharmaceuticals Ltd. stands at ₹ 3,487.48 Cr.

What is the PE ratio of Kwality Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Kwality Pharmaceuticals Ltd. is 51.78 as of the latest trailing twelve months data.

What is the ROE and ROCE of Kwality Pharmaceuticals Ltd.?

Kwality Pharmaceuticals Ltd. has a Return on Equity (ROE) of 22.61% and a Return on Capital Employed (ROCE) of 23.57% as per the latest financial reports.

What is the 52-week high and low of Kwality Pharmaceuticals Ltd.?

The 52-week high of Kwality Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Kwality Pharmaceuticals Ltd.?

The dividend yield of Kwality Pharmaceuticals Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Kwality Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 3.13%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 40.10% of Kwality Pharmaceuticals Ltd. shares.

What sector does Kwality Pharmaceuticals Ltd. belong to?

Kwality Pharmaceuticals Ltd. operates in the Healthcare sector.

What is the beta of Kwality Pharmaceuticals Ltd.?

The beta of Kwality Pharmaceuticals Ltd. is 0.58, indicating its price volatility relative to the broader market. Over the past 1 year, Kwality Pharmaceuticals Ltd. has delivered an absolute return of 210.74%.

What is the RSI of Kwality Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Kwality Pharmaceuticals Ltd. is 61.57, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Kwality Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Kwality Pharmaceuticals Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions

Holdings and Presence